Abstract: Objective To investigate the effect of trimetazidine combined with remote ischemic preconditioning(RIPC) on myocardial damage and prognosis in elderly ischemic heart disease patients undergoing percutaneous coronary intervention(PCI). Methods A total of 96 elderly ischemic heart disease patients treated with PCI were randomly divided into observation group(48 cases) and control group(48 cases) from January,2016 to September,2016.All the patients of 3 groups received antiplatelet routine drug treatment,etc.The control group received additional trimetazidine therapy,while the observation group received additional trimetazidine and RIPC.The changes of cTnI and CK-MB before and after the treatment and the incidence of adverse cardiovascular events at follow-up of 6 months were observed in both groups. Results The levels of cTnI and CK-MB increased significantly in both groups at 24 h after treatment(P<0.05),the levels of cTnI and CK-MB of the observation group was significantly lower than that at 24 h after the treatment(P<0.05);6 months follow-up showed that there were 2 cases of recurrent angina in the observation group,with an incidence of 4.17%;there were no myocardial infarction and death cases;while there were 10 cases of recurrent angina in the control group with an incidence of 20.83%,there were 5 case of myocardial infarction with an incidence of 10.42%,there was no death case. The incidence of recurrent angina and myocardial infarction of the observation group was significantly lower than that in the control group(P<0.05). Conclusion Trimetazidine combined with remote ischemic preconditioning in elderly ischemic heart disease patients after PCI can obviously reduce the levels of cTnI and CK-MB,reduce the myocardial damage and incidence of adverse cardiovascular events.